Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
CME credits: 1.00
Valid until: 20-10-2027
Claim your CME credit at https://reachmd.com/cme/nephrology/the-edema-question-selecting-a-potassium-binder-in-patients-with-hf-or-congestion/70427/ (https://reachmd.com/cme/nephrology/the-edema-question-selecting-a-potassium-binder-in-patients-with-hf-or-congestion/70427/)
This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
20 Oct 2026
From Lab Alert to Action Plan: Monitoring Potassium Without Undermining Cardiorenal Protection
CME credits: 1.00
Valid until: 20-10-2027
Claim your CME credit at https://reachmd.com/cme/nephrology/from-lab-alert-to-action-plan-monitoring-potassium-without-undermining-cardiorenal-protection/70430/ (https://reachmd.com/cme/nephrology/from-lab-alert-to-action-plan-monitoring-potassium-without-undermining-cardiorenal-protection/70430/)
This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
20 Oct 2026
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
CME credits: 1.00
Valid until: 20-10-2027
Claim your CME credit at https://reachmd.com/cme/nephrology/differentiating-oral-potassium-binders-mechanism-onset-and-sodium-load/70426/ (https://reachmd.com/cme/nephrology/differentiating-oral-potassium-binders-mechanism-onset-and-sodium-load/70426/)
This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
Who has been a guest on ReachMD CME
Names identified in recent episode analyses. Showing up to five guests.
Dr Jane Doe
Dr Anna Longer
Dr Marc A Riedl
Dr Samuel Chen
Fernanda P Silveira
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.3 / 5
3 ratings
Spotify
4.0 / 5
1 ratings
Podcast Authority Score: 34 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
33
Social presence
0
YouTube
0
Engagement
85
Contact ReachMD CME
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Questions about ReachMD CME
Who hosts ReachMD CME?
Dr John Smith and Dr Marcus Maurer host the show. Published by ReachMD.
How often do new episodes come out?
The show publishes weekly, based on its RSS feed.
Does ReachMD CME take guests?
The show does not typically feature guests, based on episode analyses.
Host of ReachMD CME?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
